|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutations in the thrombopoietin receptor gene (myeloproliferative leukemia, MPL) have been reported in patients with JAK2 V617F-negative chronic myeloproliferative disorders (MPDs).
|
21326037 |
2011 |
|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia.
|
21712540 |
2011 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available TKIs.
|
20564073 |
2010 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although strategies to overcome resistance-mediated T315I mutation may improve the survival of BCR-ABL-positive leukemia patients, there is little information on cell-based studies.
|
20471447 |
2010 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.
|
19541823 |
2009 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Some emerging aurora kinase inhibitors, such as VX-680, PHA-739358, MK-0457 and AS703569, and Smo1 and Hedgehog (Hh) inhibitors promise clinical efficacy against the Bcr-Ab T315I mutant form and leukaemia stem cells, respectively.
|
19959093 |
2009 |
|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia.
|
19691103 |
2009 |
|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01).
|
17229652 |
2007 |
|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Homozygous V617F mutation is associated with the clinical picture of classic PV and with a higher tendency to secondary myelofibrosis, but with no increased leukemia unless other biological or genetic factors come into play, such as myelosuppressive agents or the acquisition of additional biologic or genetic defects.
|
16810614 |
2006 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
More importantly, ON012380 was found to induce apoptosis of all of the known imatinib-resistant mutants at concentrations of <10 nM concentration in vitro and cause regression of leukemias induced by i.v. injection of 32Dcl3 cells expressing the imatinib-resistant BCR-ABL isoform T315I.Daily i.v. dosing for up to 3 weeks with a >100 mg/kg concentration of this agent is well tolerated in rodents, without any hematotoxicity.
|
15677719 |
2005 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The resistance to the tyrosine kinase inhibitor imatinib in BCR/ABL-positive leukemias is mostly associated with mutations in the kinase domain of BCR/ABL, which include the most prevalent mutations E255K and T315I.
|
15194504 |
2004 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We investigated the risks of adult leukemia with genetic polymorphisms of folate metabolic enzymes (MTHFR C677T, A1298C, and TS) and evaluated if the associations varied by dietary folate intake from a multicenter case-control study conducted in Chinese.
|
26438060 |
2016 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population.
|
22441130 |
2012 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Recipient MTHFR polymorphisms (C677T) were associated with acute GvHD (P=0.03), and recipient VDR TaqI with TRM and overall survival (P=0.006 and P=0.04, respectively).Genetic factors that interfere with drug metabolisms are associated with treatment-related toxicities, GvHD and survival after HLA-identical HSCT in patients with leukemia and should be investigated prospectively.
|
19005482 |
2009 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.
|
17395259 |
2008 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our results suggest that the MTHFR C677T polymorphism displays a similar distribution pattern in lymphoid and myeloid leukemias and that the frequency of the homozygote variant genotype (677TT) is lower in all leukemia types.
|
15068389 |
2003 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate.
|
12453860 |
2002 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In contrast, associations for A1298C homozygotes (CC; OR = 0.26 with a 95% CI of 0.07--0.81) and C677T homozygotes (TT; OR = 0.49 with a 95% CI of 0.20--1.17) were observed for hyperdiploid leukemias (n = 138).
|
11274424 |
2001 |
|
rs121434592
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Recently, the E17K mutation in the AKT1 has been associated with multiple human malignancies and leukemia in mice.
|
20440266 |
2010 |
|
rs121434592
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway.
|
19461960 |
2009 |
|
rs121434592
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.
|
18665177 |
2008 |
|
rs121434592
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The E17K change results in constitutive AKT1 activation and induces leukaemia in mice.
|
18504432 |
2008 |
|
rs121434592
|
|
|
0.050 |
GeneticVariation |
BEFREE |
They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice.
|
17921701 |
2007 |
|
rs113488022
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |
|
rs121913377
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |